Axa Has $12.38 Million Position in United Therapeutics Corporation (UTHR)

Axa lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.1% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 95,429 shares of the biotechnology company’s stock after buying an additional 1,000 shares during the quarter. Axa owned approximately 0.22% of United Therapeutics Corporation worth $12,380,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Nomura Asset Management Co. Ltd. lifted its stake in shares of United Therapeutics Corporation by 0.3% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after buying an additional 40 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of United Therapeutics Corporation by 1.4% during the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 45 shares in the last quarter. Argent Capital Management LLC lifted its stake in shares of United Therapeutics Corporation by 2.4% during the 1st quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 60 shares in the last quarter. Synovus Financial Corp lifted its stake in shares of United Therapeutics Corporation by 1.2% during the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock valued at $731,000 after buying an additional 69 shares in the last quarter. Finally, Ifrah Financial Services Inc. lifted its stake in shares of United Therapeutics Corporation by 1.7% during the 2nd quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock valued at $576,000 after buying an additional 76 shares in the last quarter.

A number of research analysts recently weighed in on UTHR shares. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, UBS AG restated a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Six equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $134.50.

ILLEGAL ACTIVITY WARNING: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/2886499/axa-has-12-38-million-position-in-united-therapeutics-corporation-uthr.html.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 120.75 on Tuesday. The stock has a 50 day moving average of $130.11 and a 200-day moving average of $130.35. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The company has a market capitalization of $5.25 billion, a P/E ratio of 14.00 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $4.42 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post $10.09 EPS for the current year.

In other news, Director Raymond Dwek sold 3,490 shares of the stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $131.71, for a total value of $459,667.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,238 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $130.20, for a total transaction of $161,187.60. Following the completion of the sale, the chief executive officer now owns 1,378 shares of the company’s stock, valued at $179,415.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,178 shares of company stock worth $3,289,427. Insiders own 7.80% of the company’s stock.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.